



23rd National Conference on Pharmaceutical and Chemical Diversion Dallas, Texas

December 13, 2017
CDR Karen Hearod



Assistant Secretary Priorities: Opioid Crisis

- Support for evidence-based prevention, treatment, recovery services
 - STR grants to states
 - Block grants to states
 - TA to states on EBPs – MAT, psychotherapies, PDMP, toxicology screens
 - Naloxone access/First Responders/Peers
 - Pregnant/post partum women/NAS
 - Criminal justice programs
 - Recovery Housing
 - Training programs – ATTCs, PCSS, CIHS

Assistant Secretary Priorities: Opioid/Other Substances

- Establishment of EBP in clinical practice – MAT and psychosocial therapies
- Clinician/state government partnerships
- Review of SAMHSA initiatives with other substances

Assistant Secretary Priorities: SMI


- ***Early Intervention/Ongoing support:***
 - FEP programs, ACT, crisis intervention programs
 - Integrated care
 - Diversion from incarceration to care
 - Access to care: parity
 - Transitional Age Youth
- ***Effective medical treatment of psychosis***
 - Clozapine for treatment refractory schizophrenia
 - Long acting medications
 - AEs: Metabolic syndrome/Medical illnesses/Tobacco/Co-occurring SUDs
- ***Suicide Prevention***
 - Understanding links between poorly treated pain, depression, addiction, and suicidality
 - Zero suicide – Focus on veterans and service members

DPT Federal Regulatory Oversight

The Center for Substance Abuse Treatment's (CSAT) Division of Pharmacologic Therapies (DPT) manages the day-to-day oversight activities necessary to implement federal regulations on the use of substance use disorder medications such as methadone and buprenorphine.

- This activities include supporting the accreditation and certification of more than 1,500 opioid treatment programs (OTPs) that collectively treat more than 300,000 patients each year under 42 CFR Part 8.

DPT Federal Regulatory Oversight



- Federal Regulation - 42 CFR § Part 8

§ http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=3&SID=7282616ac574225f795d5849935efc45&ty=HTML&h=L&n=pt42.1.8&r=PART#se42.1.8_112

- Federal Guidelines for OTPs - 2015

§ <http://store.samhsa.gov/product/Federal-Guidelines-for-Opioid-Treatment-Programs/PEP15-FEDGUIDEOTP>

Certification

To become an OTP, the program must be approved by:

1. The state opioid treatment authority (SOTA)
 - *Each state has their own rules.*
2. DEA Regional Office
3. SAMHSA/DPT - 42 CFR § 8.11
4. Accrediting Body
 - *Choose a SAMHSA-approved accrediting body*
 - *Receive accreditation within 1 year of provisional certification timeframe from SAMHSA*

Provisional Certification

- SMA-162 application (on-line)
<http://dpt2.samhsa.gov/sma162/>
- An OTP shall submit the information required by 42 CFR § 8.11 (b) to SAMHSA along with supporting documents.

Certification and Treatment Standards

SAMHSA-approved OTPs are evaluated on the following Federal standards:

- *Administrative and Organizational*
- *Continuous Quality Improvement*
- *Staff Credentials*
- *Patient Admission Criteria*
- *Required Services*
- *Recordkeeping and Patient Confidentiality*
- *Medication Administration, Dispensing and Use*
- *Interim Maintenance Treatment*

Accreditation

- An accreditation body (AB) is an organization that has been approved by SAMHSA under § 8.3 to accredit OTPs.
- There are currently 6 SAMHSA-approved ABs:
 - *CARF*
 - *COA*
 - *Joint Commission*
 - *Missouri*
 - *NCCHC*
 - *Washington*

Total Active OTPs as of 31st December



OTP Compliance Officers By HHS Region

Barbara Howes (Acting)

240-276-2547

Barbara.Howes@samhsa.hhs.gov

Region 1:

CT, ME, MA, NH, RI, VT

Region 2: NJ, NY, PR, VI

Wilmarie Hernandez

240-276-2751

Wilmarie.Hernandez@samhsa.hhs.gov

Region 3:

DE, DC, MD, PA, VA, WV

Region 10:

AK, ID, OR, WA

Ivette Ruiz

240-276-1511

Ivette.Ruiz@samhsa.hhs.gov

Region 4:

AL, FL, GA, KY, MS, NC, SC, TN

Region 7:

IA, KS, MO, NE

William Longinetti

(Presidential Fellow)

240-276-2547

William.Longinetti@samhsa.hhs.gov

Region 5:

IL, IN, MI, MN, OH, WI

Region 6:

AR, LA, NM, OK, TX

Mary Lou Ojeda

240-276-2894


Marylou.Ojeda@SAMHSA.hhs.gov

Region 8:

CO, MT, ND, SD, UT, WY

Region 9:

AZ, CA, HI, GU, NV, AS, CNMI



Agency Resources

- State Opioid Treatment Authority
<http://dpt2.samhsa.gov/regulations/smalist.aspx>
- State Single State Agency
<http://nasadad.org/ssa-web-sites/>
- Drug Enforcement Administration
<https://www.dea.gov/about/Domesticoffices.shtml>


Treatment Locators

- SAMHSA Behavioral Treatment Services Locator
<https://findtreatment.samhsa.gov/>
- Opioid Treatment Locator
<http://dpt2.samhsa.gov/treatment/directory.aspx>
- Buprenorphine Treatment Practitioner Locator
<https://www.samhsa.gov/medication-assisted-treatment/physician-program-data/treatment-physician-locator>

DPT Regulatory Branch

DATA Waived Practitioners

2017 DATA Certified Practitioners



275 DATA Waived Physicians


Physicians with a 275 DATA waiver are required to submit an annual report due on their anniversary date.

Each physician receives an email notification when their anniversary date is approaching to remind them to submit the report.

NP/PA DATA Waivered 2017

- As of February 2018, NP/PAs will be able to apply for a patient increase to a 100 limit when they reach their anniversary date.

PA/NP at the 30 Patient Level



■ PA ■ NP

Buprenorphine Resources

Buprenorphine Help Desk

1-866-287-2728

infobuprenorphine@samhsa.hhs.gov

DEA Waiver Related Questions

202-307-5231

Applying for a waiver

<http://buprenorphine.samhsa.gov/forms/select-practitioner-type.php>